The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

Potential Fall-Back Option Of SRP-9003 For The Treatment Of Patients With Limb Girdle Muscular Dystrophy There is one other reason why I have a Hold rating on Sarepta Therapeutics, and that is ...

Satellos CEO Frank Gleeson said: “Given the short 28-day treatment window ... of functional muscle tissue. There are some approved gene therapies for DMD, including Roche and Sarepta’s ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

But, the longevity of the treatment is a concern for providers ... of treating patients earlier.” Though there is no requirement for DMD newborn screening in Arizona, Castle has been active ...

Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces ... This is in Phase 1 development. Then there are engineered exosomes for RNA, protein, and small molecule delivery.

Dystrophin's isoforms are thought to contribute variably to neuropsychiatric disorders, behavioral disorders, and ...

For many, a visit to the dentist brings fear, anxiety, or memories of uncomfortable experiences. But dentistry is ...

There is no known cure for Duchenne muscular dystrophy and currently approved treatment aims to control symptoms to improve quality of life. Sarepta Therapeutics’ Exondys 51 (eteplirsen ...

Muscular dystrophy, known as DMD, is a rare and fatal genetic disease that primarily affects boys, slowly robbing them of their ability to walk, breathe and live independently. Until now ...